These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 38837528

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review.
    Salim A, Hennessy E, Sonneborn C, Hogue O, Biswas S, Mays M, Suneja A, Ahmed Z, Mata IF.
    CNS Drugs; 2024 Jun; 38(6):481-491. PubMed ID: 38583127
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study.
    Charleston L, Talon B, Sullivan C, Anderson C, Kymes S, Regnier SA, Soni-Brahmbhatt S, Nahas SJ.
    J Headache Pain; 2023 Aug 02; 24(1):101. PubMed ID: 37532991
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review.
    Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L, Manack Adams A.
    Pain Ther; 2021 Dec 02; 10(2):809-826. PubMed ID: 33880725
    [Abstract] [Full Text] [Related]

  • 8. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.
    Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F.
    CNS Drugs; 2022 Feb 02; 36(2):191-202. PubMed ID: 35146696
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine.
    Argyriou AA, Dermitzakis EV, Xiromerisiou G, Vikelis M.
    Toxins (Basel); 2022 Dec 02; 14(12):. PubMed ID: 36548744
    [Abstract] [Full Text] [Related]

  • 14. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G, Croop R, Kudrow D, Halverson P, Lovegren M, Thiry AC, Conway CM, Coric V, Lipton RB.
    Headache; 2020 Sep 02; 60(8):1734-1742. PubMed ID: 32799325
    [Abstract] [Full Text] [Related]

  • 15. Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysis.
    Scheffler A, Basten J, Menzel L, Binz D, Becker WA, Breunung V, Schenk H, Kleinschnitz C, Nsaka M, Lindner D, Holle D.
    J Headache Pain; 2024 Jul 04; 25(1):109. PubMed ID: 38965463
    [Abstract] [Full Text] [Related]

  • 16. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
    Schoenen J, Manise M, Nonis R, Gérard P, Timmermans G.
    Rev Neurol (Paris); 2020 Dec 04; 176(10):788-803. PubMed ID: 32758365
    [Abstract] [Full Text] [Related]

  • 17. The introduction of the CGRP monoclonal antibodies and their effect on the prescription patterns of chronic migraine preventive medications in a tertiary headache center: A retrospective, observational analysis.
    Moskatel LS, Graber-Naidich A, He Z, Zhang N.
    Headache; 2024 Feb 04; 64(2):188-194. PubMed ID: 37882379
    [Abstract] [Full Text] [Related]

  • 18. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study.
    Vernieri F, Brunelli N, Messina R, Costa CM, Colombo B, Torelli P, Quintana S, Cevoli S, Favoni V, d'Onofrio F, Egeo G, Rao R, Filippi M, Barbanti P, Altamura C.
    J Headache Pain; 2021 Dec 18; 22(1):154. PubMed ID: 34922444
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.